News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif.
View HTML
Toggle Summary ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
SAN CARLOS, Calif. , May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS ® (avacopan), an orally administered selective complement 5a receptor (C5aR)
View HTML
Toggle Summary ChemoCentryx Announces Changes to its Board of Directors
-- David E. Wheadon , M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell , Jr., to Retire from Board -- SAN CARLOS, Calif. , May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors.
View HTML
Toggle Summary ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-- Supports plans to advance TAVNEOS ® (avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif. , May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that a poster
View HTML
Toggle Summary ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
SAN CARLOS, Calif. , May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET .
View HTML
Toggle Summary ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif. , May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS ® (avacopan), an orally
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
SAN CARLOS, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients -- SAN CARLOS, Calif.
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS ® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering
View HTML